Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226967 · ClinicalTrials.gov registry record
Stress, Diurnal Cortisol, and Breast Cancer Survival
A clinical trial of Breast Cancer, sponsored by Stanford University.
- Completed
- Registry status
- 115
- Enrollment target
- 1
- Study location
NCT00226967: Completed study of Breast Cancer, sponsored by Stanford University.
NCT00226967 is a study of Breast Cancer that has completed, run by Stanford University. The registered enrollment target is 115 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226967, a study of Breast Cancer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.
Conditions Studied
Interventions
- DRUG Sandostatin
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2002-09-08 |
| Est. Completion | 2005-12 |
What the finished NCT00226967 record still lists
NCT00226967 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sandostatin is the first listed.
NCT00226967 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00226967 about?
NCT00226967 is a clinical study titled "Stress, Diurnal Cortisol, and Breast Cancer Survival". The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.
What is the current status of trial NCT00226967?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2002-09-08. Estimated completion is 2005-12.
What conditions does trial NCT00226967 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00226967?
The interventions under investigation include: Sandostatin (DRUG).
Who is sponsoring clinical trial NCT00226967?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00226967 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00226967's enrollment target sits among peer trials
115 523rd of 1224 higher than 697 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI